Tianxiao Peter Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tianxiao Peter Yang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- David S. Eisenberg
UCLA
3 shared publications Duilio Cascio
University of California, Los Angeles
3 shared publicationsChristopher Kazu Williams
University of California, Los Angeles, United States
2 shared publicationsDennis W. Dickson
Mayo Clinic
2 shared publicationsHarry V. Vinters
University of California, Los Angeles, United States
2 shared publications- Michael R. Sawaya
Department of Chemistry and Biochemistry, University of California, Los Angeles
2 shared publications
Latest Publications
- Open Access
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (31) , 10662-10676
Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (31) , 10662-10676
Open AccessCrystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease
- Open Access
- 1 November 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (44) , 16451-16464
Structure-based inhibitors halt prion-like seeding by Alzheimer’s disease–and tauopathy–derived brain tissue samples
- 1 November 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (44) , 16451-16464
Open AccessStructure-based inhibitors halt prion-like seeding by Alzheimer’s disease–and tauopathy–derived brain tissue samples
- Open Access
- 15 October 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Structure-based inhibitors of amyloid beta core suggest a common interface with tau
Alzheimer’s disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the disease, and ultimately gives way to the formation of tau tangles which track with cognitive decline in humans. Here, we report the crystal structure of an Aβ core segment determined by MicroED and in it, note characteristics of both fibrillar and oligomeric structure. Using this structure, we designed peptide-based inhibitors that reduce Aβ aggregation and toxicity of already-aggregated species. Unexpectedly, we also found that these inhibitors reduce the efficiency of Aβ-mediated tau aggregation, and moreover reduce aggregation and self-seeding of tau fibrils. The ability of these inhibitors to interfere with both Aβ and tau seeds suggests these fibrils share a common epitope, and supports the hypothesis that cross-seeding is one mechanism by which amyloid is linked to tau aggregation and could promote cognitive decline.
- 15 October 2019
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 8
Open AccessStructure-based inhibitors of amyloid beta core suggest a common interface with tau
Alzheimer’s disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the disease, and ultimately gives way to the formation of tau tangles which track with cognitive decline in humans. Here, we report the crystal structure of an Aβ core segment determined by MicroED and in it, note characteristics of both fibrillar and oligomeric structure. Using this structure, we designed peptide-based inhibitors that reduce Aβ aggregation and toxicity of already-aggregated species. Unexpectedly, we also found that these inhibitors reduce the efficiency of Aβ-mediated tau aggregation, and moreover reduce aggregation and self-seeding of tau fibrils. The ability of these inhibitors to interfere with both Aβ and tau seeds suggests these fibrils share a common epitope, and supports the hypothesis that cross-seeding is one mechanism by which amyloid is linked to tau aggregation and could promote cognitive decline.